Nuclera, the Cambridge-based biotechnology company focused on accelerating protein expression and optimisation, has appointed William J. Kullback to its Board of Directors. The appointment comes as the company implements its global commercial strategy following a successful $75 million series C funding round.

Financial leadership enhances commercial trajectory

Kullback brings over three decades of financial executive experience to Nuclera, with particular expertise in life science tools and medical devices. As current CFO at Telesis Bio, a company specialising in automated synthesis technology for therapeutic discovery, he has demonstrated significant operational restructuring capabilities, achieving approximately 70% reduction in operational expenses.

His previous role as CFO at BioLegend Inc., a worldwide provider of antibodies and life science reagents, saw him manage the company’s $5.25 billion sale to NYSE-listed Revvity (previously PerkinElmer) – the largest acquisition in Revvity’s history. Dr Michael Chen, CEO and co-founder of Nuclera, highlighted the strategic importance of the appointment: “Bill’s experience will be invaluable to Nuclera as we scale to address current challenges in protein production by bringing eProtein Discovery to even more researchers.”

William J. Kullback

Protein discovery platform aims to transform workflows

The eProtein Discovery system – Nuclera’s benchtop platform – represents a significant advancement in protein expression technology for laboratory researchers. The system is designed to streamline and accelerate protein production processes that are essential to drug discovery and development workflows.

Kullback expressed enthusiasm about joining Nuclera at this critical juncture: “Nuclera’s eProtein Discovery has the potential to transform drug discovery workflows. The Company is at an exciting stage as it expands globally and I am looking forward to working with the team to support the Company’s growth and drive success at this pivotal stage in Nuclera’s development.”

Commercial expansion supports protein science advancement

With the protein expression market continuing to grow in importance across therapeutic development, diagnostic advancement, and fundamental research, Nuclera’s commercial expansion strategy aligns with increasing demand for efficient protein production technologies.

Kullback’s appointment reinforces the company’s focus on sustainable growth and strategic financial management as it seeks to bring its technology to a broader range of research institutions and bio-
technology companies worldwide.